Fulgent Genetics, Inc. FLGT
NASDAQ · United States · Health Services
$21.96-0.07 (-0.30%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
The latest update on Fulgent Genetics centers on a higher analyst price target, with fair value moving from US$15 to US$19. That shift reflects refreshed views on profitability and valuation, while the Neutral rating signals that analysts see both upside potential and execution risk in balance for now. As you read on, you will see how this new target fits into the broader narrative around Fulgent Genetics and what to watch as the story develops from here. Stay updated as the Fair Value for...
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.